A Case of Severe Thrombocytopenia in a Patient with Chronic Hepatitis C Caused by a Single Administration of Pegylated Interferon Alpha 2a Subsequent to 48 Weeks of Pegylated Interferon Alpha 2b Plus Ribavirin Therapy
- 1 January 2010
- journal article
- case report
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 49 (16) , 1741-1744
- https://doi.org/10.2169/internalmedicine.49.3586
Abstract
A 54-year-old female with chronic hepatitis C developed severe thrombocytopenia after a single administration of Peg-IFN alpha 2a subsequent to 48 weeks of Peg-IFN alpha-2b plus ribavirin therapy. The platelet count decreased from 11.3 x 10(4) /mm(3) to 1.6 x 10(4) /mm(3). Blood test and bone marrow aspiration examination indicated that an immunological mechanism was considered for the etiology of platelet decrease. Fifty mg of prednisolone was administered and the platelet count gradually increased to the normal range. This case is very instructive since severe thrombocytopenia did not occur during 48 weeks of Peg-IFN alpha-2b plus ribavirin therapy, but occurred after a single subcutaneous administration of Peg-IFN alpha-2a during a subsequent course.Keywords
This publication has 10 references indexed in Scilit:
- Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic reviewBlood, 2009
- Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2007
- Peginterferon and Ribavirin for Chronic Hepatitis CNew England Journal of Medicine, 2006
- A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)Journal of Hepatology, 2006
- Helicobacter pylori eradication: Novel therapy for immune thrombocytopenic purpura? A review of the literatureAmerican Journal of Hematology, 2005
- Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximabAmerican Journal of Hematology, 2005
- Pegylating IFNs at His-34 Improves the in Vitro Antiviral Activity Through the JAK/STAT PathwayAntiviral Chemistry and Chemotherapy, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001
- Thrombocytopenia during interferon alfa therapyJAMA, 1991